Myers ER - Search Results

1

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME. Samimi G, et al. Among authors: myers er. J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11. J Clin Oncol. 2017. PMID: 28398847 Free PMC article.

2

Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.

Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER. Moss HA, et al. Among authors: myers er. Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30. Genet Epidemiol. 2018. PMID: 29193313

3

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.

Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Moorman PG, et al. Among authors: myers er. J Clin Oncol. 2013 Nov 20;31(33):4188-98. doi: 10.1200/JCO.2013.48.9021. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145348 Review.

4

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.

Foote JR, Lopez-Acevedo M, Buchanan AH, Secord AA, Lee PS, Fountain C, Myers ER, Cohn DE, Reed SD, Havrilesky LJ. Foote JR, et al. Among authors: myers er. J Oncol Pract. 2017 Feb;13(2):e120-e129. doi: 10.1200/JOP.2016.011866. Epub 2017 Jan 3. J Oncol Pract. 2017. PMID: 28045615

5

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA. Gamble C, et al. Among authors: myers er. Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11. Ann Surg Oncol. 2017. PMID: 28699130 Free PMC article.

6

Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.

Dottino JA, Cliby WA, Myers ER, Bristow RE, Havrilesky LJ. Dottino JA, et al. Among authors: myers er. Gynecol Oncol. 2015 Sep;138(3):694-9. doi: 10.1016/j.ygyno.2015.06.013. Epub 2015 Jun 10. Gynecol Oncol. 2015. PMID: 26072441

7

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. Saslow D, et al. Among authors: myers er. Am J Clin Pathol. 2012 Apr;137(4):516-42. doi: 10.1309/AJCPTGD94EVRSJCG. Am J Clin Pathol. 2012. PMID: 22431528

8

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ. Secord AA, et al. Among authors: myers er. Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd. Int J Gynecol Cancer. 2013. PMID: 23666017

9

Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers.

Jewell EL, Smrtka M, Broadwater G, Valea F, Davis DM, Nolte KC, Valea R, Myers ER, Havrilesky LJ. Jewell EL, et al. Among authors: myers er. Int J Gynecol Cancer. 2013 Jul;23(6):1158-66. doi: 10.1097/IGC.0b013e318299e2a6. Int J Gynecol Cancer. 2013. PMID: 23792609

10

Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.

Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND. Havrilesky LJ, et al. Among authors: myers er. Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6. Gynecol Oncol. 2017. PMID: 28390820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

287 results

Search Page